Santiago Pla

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies

Part of Infinity Pharmaceuticals, Inc., Biofrontera Pharma GmbH is a German company that provides natural products drug discovery services. The company is based in Leverkusen, Germany. The CEOs are María del Pilar de la Huerta Martínez, Montserrat Foguet. The company was founded in 2003. Biofrontera Pharma was acquired by Discovery Partners International, Inc. from Biofrontera AG on June 30, 2005.

Antibióticos de León SLU develops, manufactures, sells, and distributes active pharmaceutical ingredients for penicillin-based antibiotics. Its products include sterile antibiotics and oral semisynthesis. The company was founded in 2014 and is headquartered in Leon, Spain.

Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain.

Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain.

Glutenostics LLC engages in the manufacture of urine and stool test products and retail through online. The company was founded by Angel Cebolla Ramirez and Francisco Leon in 2016 and is headquartered in Los Angeles, CA.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Celimmune LLC is a private company that engages in treating and preventing autoimmune diseases. The company is based in Lebanon, NJ. The company was founded by Ashleigh W. Palmer, Francisco Leon.

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Bionova Capital SCR SA. (Bionova Capital) is a venture capital firm founded in 2015. It was previously known as Hovione Capital. The firm is headquartered in Lisbon, Portugal.